Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Phase 2Active Not RecruitingNCT07150845

Evommune, Inc.120 enrolled

Overview

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

120

Conditions

Atoptic Dermatitis

Interventions

EVO756DRUG

Dose 1

EVO756DRUG

Dose 2

EVO756DRUG

Dose 3

Placebo controlDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic AD that has been present for ≥6 months * Validated-Investigator's Global Assessment score of ≥3 * EASI of ≥16 * BSA of AD involvement of ≥10% Exclusion Criteria: * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening * Use of certain medications * Presence of skin comorbidities or other condition(s) that may interfere with study assessments * Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Locations (29)

Outcomes

Primary Outcomes

Percentage change in Eczema Area and Severity Index (EASI) from Baseline

Time frame: Week 12

Secondary Outcomes

Percentage change in EASI from Baseline

Time frame: Weeks 2, 4, and 8

Mean changes in EASI from Baseline

Time frame: Week 2, 4, 8, and 12

Proportion of subjects with EASI-50, EASI-75, and EASI-90 from Baseline